Jenny Seligmann
@JenSeligmann
Followers
1K
Following
4K
Media
99
Statuses
972
Optimist. Prof GI medical oncology. Coffee, Irn-Bru & dog enthusiast @foxtrotstudy @focus4trial @ArielTrial #pelotonuk 🇪🇺
Edinburgh born, Leeds based
Joined October 2014
Thanks for all the positive messages re FOCUS4C. Beyond delighted to see this in @guardian
theguardian.com
Adavosertib found to delay tumour growth in some patients in clinical trial, with few side effects
1
10
45
🆕Article of the Month podcast🎧: @tompowles1 discusses the FOxTROT trial in locally advanced colon cancer with @JenSeligmann
https://t.co/lBPCs1rfXk For the full study report see: https://t.co/iHqyDjfwSE
0
2
7
#ESMO25 @myESMO A pleasure to join this symposium with @JenSeligmann & Julien Taieb ➡️ more choices in refractory mCRC ✅ ➡️ needs a tailored approach to optimize tx @TakedaOncology
@myESMO
#ESMOAmbassador
0
5
20
Neoadjuvant IO for locally advanced MSS colon ca…. This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection. 💥💥huge congrats to my team neoadjuvant dear friend and team! We will get there in colon cancer
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: https://t.co/KR6mBytwV3 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
1
4
15
My take homes.... Further support of neoadjuvant IO esp for high risk pts Chemo no or limited role for dMMR early CC (?ATOMIC strategy) Clinical staging CAN identify high risk pts 20% recurrence relevant when effective rx available! @MyriamChalabi @CRUKresearch @oncodaily
0
3
5
Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC -Neoadjuvant IO superior to chemo -20% relapses with chemo in "good prognosis" group; 30% if T4 -Minimal path response to chemo - Clinical staging identified high risk group
2
17
64
Thanks for highlighting!! @MyriamChalabi
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%
1
1
4
Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. https://t.co/8nGqi5U03Z
0
6
19
0
0
0
🤔Pani had little effect on path response 👍Prospective trial in LACC RAS/RAF-wt EREG/AREG pts planned ❓Consider in LARC This will be my last tweet - hope to see you on Bluesky 👋 @b
1
0
2
🎆 Now online - my 2 fav topics in one paper 👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer 👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts ❓Time to re-think targeted agents in LACC/LARC https://t.co/wDhAkgCYw5
annalsofoncology.org
The FOxTROT trial has reported advantages of neoadjuvant chemotherapy (NAC) in locally advanced colon cancer (LACC). In this article, we present results of the embedded randomised phase II trial...
1
7
34
Just finished. Very interesting #MiniOral #ESMOAsia24 session in #PDAC and #Biliary that I had the pleasure to co-chair (and discuss) with @JenSeligmann Posts coming with my thoughts 😉 Thanks @LorenzaRimassa for the 📸 🫶 @myESMO
The mini oral session on #GI cancer continues at #ESMOAsia24 in #Singapore. More abstracts on gastric, gastroesophageal, and GEJ cancer, but also on #BTC and #PDAC @myESMO @DrAngelaLamarca @JenSeligmann
0
6
25
Check out our editorial on high-risk stage II colon cancer: a call for clinicians to exercise caution when withdrawing oxaliplatin and when interpreting subanalyses https://t.co/h8iSwqWGLt
@DrClaireGallois @JenSeligmann
0
2
6
Epic @chrisjmwilliams leading this 👍🏻 Very timely review post #ESMO24 neoadjuvant colon IO data! Delighted to be involved plus international 🤝 @NatRevClinOncol @OncoAlert @LIMRLeeds
0
3
10
Neoadjuvant immunotherapy for msi-h colon and rectal cancer 👍🏻 But emerging data on complications not seen with chemo Project initiated after a pt developed bowel obstruction due to stricturing response to IO ➡️emergency resection ➡️pCR 👏@Jplatt_19 & our international 🤝
Delighted to have this published. Fantastic effort from all involved! ✅ ICIs transforming Tx of dMMR CRC ✅ Common toxicities now well recognised but... 💥 Is bowel obstruction a rare complication when primary tumour in situ?! International case series in @ESMO_Open ⬇️⬇️⬇️
1
11
39
Tumour immune markers absolutely relevant in risk stratification for early stage colon cancer ✅ Great collaboration with @RocheDiaUSA @UniversityLeeds 👏👏@chrisjmwilliams published in @JCO_ASCO 🤩
0
1
11
Plus a mystery LBA in this session…🤩 💥💥💥 Can’t wait #ESMO24
Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session + more neoadj IO from Imhotep, and wonderful @JenSeligmann as discussant. Stay tuned for more exciting💥💥💥news!
1
3
13
How to integrate NACT in locally advanced colon cancer: 👉 enroll pts in clinical trials 👉 gain experience 👉 MDT is crucial @JenSeligmann
#ESMOGI24 @myESMO
0
7
22
🙏🏽🙏🏽@ChiaraCrem1 That’s a wrap for day 1 of #ESMOGI24 Privilege to share the stage with @JeanneTie to discuss advances in localised colon cancer @FoxtrotStudy @DucreuxMichel
Outstanding presentation by @JenSeligmann at #ESMOGI24 about neoadj strategies to modify the status quo in localized colon cancer. Academic research will be the key, sure! 💪🏻 @myESMO #ESMOAmbassadors
1
5
34
Halfway there! I'm pleased to announce 10 out of our 20 selected sites have now opened to FOxTROT 4! Great job to everyone involved!👏👏👏 @LeedsCTRU @JenSeligmann @Janetgr83596731 @PierreFabre @merckgroup
0
3
15
Congratulations to Dr Niki Christou and the team in France who have randomised their first FOxTROT 2 participant! 🎉🎉🎉 I'm also pleased to announce that our Indian team have a total of 4 randomised participants! An amazing effort by both teams. 👏👏👏
1
4
9